BioNTech (NASDAQ:BNTX) Trading Down 0.3% - What's Next?

BioNTech SE (NASDAQ:BNTX) saw its shares decline by 0.3% during mid-day trading on Wednesday. The stock reached a low of $114.04 and was last reported at $115.30. During this trading session, around 65,586 shares changed hands, which is a significant drop of 92% compared to its average daily trading volume of 810,809 shares. The previous closing price was $115.59.

Wall Street Analysts Project Future Growth

Several financial analysts have shared insights regarding BioNTech’s stock performance. UBS Group recently raised their price target for BioNTech from $97.00 to $131.00, assigning it a "neutral" rating in a report dated September 18th. Similarly, Jefferies Financial Group upgraded BioNTech from a "hold" to a "buy" rating and increased their price objective from $96.00 to $150.00 in a report on September 17th. Moreover, HC Wainwright maintained a "buy" rating while setting a target price of $150.00 on November 18th. Furthermore, Morgan Stanley upgraded BioNTech from an "equal weight" rating to "overweight," raising their target price from $93.00 to $145.00 on September 24th. Bank of America also adjusted their price target, increasing it from $125.00 to $150.00, and gave a "buy" rating on September 16th. Overall, four analysts have rated the stock as hold, eleven as buy, while one has assigned a strong buy rating. According to MarketBeat.com, BioNTech has an average rating of "Moderate Buy" with an average target price of $138.67.

BioNTech's Performance Data

The company's 50-day moving average is recorded at $113.83, with a 200-day moving average of $99.12. BioNTech holds a market capitalization of $27.55 billion, with a P/E ratio of -54.90 and a beta value of 0.22. The company's debt-to-equity ratio stands at 0.01, and it boasts a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech released its latest earnings report on November 4th, showing earnings per share (EPS) of $0.81 for the quarter, surpassing analysts' expected EPS of ($1.26) by $2.07. The company suffered a negative net margin of 15.16% and a negative return on equity of 2.35%. It reported revenues of $1.24 billion during the quarter, significantly exceeding analyst predictions of $514.08 million. In comparison, the revenue was up by 38.9% from the same period last year, while EPS from the same quarter last year was $0.73. Analysts forecast that BioNTech SE will end the current fiscal year with an estimated EPS of -3.72.

Institutional Investors' Activity

Recently, various institutional investors and hedge funds have adjusted their positions in BioNTech. For instance, GAMMA Investing LLC boosted its stake in BioNTech by 21.7% during the 3rd quarter, now owning 623 shares valued at $74,000 after acquiring an additional 111 shares. EverSource Wealth Advisors LLC increased its stake by 106.3% in the 1st quarter, resulting in ownership of 489 shares valued at $43,000 after buying 252 more shares. Blue Trust Inc. significantly raised their holdings by 491.1% in the 3rd quarter, acquiring 467 shares worth $55,000, after purchasing an additional 388 shares. Similarly, Gallacher Capital Management LLC upped its stake in the 2nd quarter by 12.1%, now owning 3,657 shares valued at $294,000. Additionally, TD Asset Management Inc. grew its holdings by 6.1% during the same period, owning 7,590 shares worth $612,000. Overall, institutional investors and hedge funds manage about 15.52% of BioNTech's shares.

About BioNTech SE

BioNTech SE is a biotechnology firm focused on developing and commercializing immunotherapies aimed at treating cancer and infectious diseases. The company is actively working on several FixVac product candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112 in Phase I/IIa trials for prostate cancer; BNT113 in Phase II trials to combat HPV 16+ head and neck cancers; BNT114 targeting triple negative breast cancer; BNT115 in Phase I trials for ovarian cancer; and BNT116, also in Phase I trials but for non-small cell lung cancer.

BioNTech, Stocks, Earnings, Analysis, Traders